The Asia Pacific Antimicrobial Resistance Diagnostics Market should witness market growth of 7.1% CAGR during the forecast period (2022-2028).
The use of antibiotics in the management of chronic diseases such as diabetes, rheumatoid arthritis, and asthma as well as organ transplants, joint replacements, and cancer therapy all depend on this ability. Sometimes there is no cure for certain infections. Healthcare professionals would no longer be capable of treating infections and managing these risks to public health if antifungals and antibiotics lost their effectiveness.
Diagnostics enable the right use of novel medications when they are brought into medical care all through their commercial lifecycle. It is crucial for medical professionals and treating doctors to know patient-specific beneficial treatments. Similarly, it is crucial for antimicrobial stewardship boards to know how to fulfil the needs of all patients at the institutions with regard to resistance. Even if a drug were available and capable of saving patients' lives, it might not be taken at all or be misused without a diagnostic tool that can determine if a patient will likely benefit from it.
As it restricts the access of patients and settings to antimicrobials to only those situations in which the medications are likely to enhance an individual's health condition, appropriate usage is fundamental in the control of antimicrobial resistance. The likelihood that a drug's effectiveness will decrease owing to resistance increases the more inadequately antimicrobials are used. Diagnostics aid the medical community in maintaining the usefulness of these priceless medications due to the enormous number of resources and time needed to identify new effective and safe antibiotics.
Several patients in India can no longer receive an advantage from carbapenem, a potent antibiotic used mostly in intensive care units to treat pneumonia and septicemia since they have grown resistant to it. This was stated in research by the Indian Council of Medical Research (ICMR). This is concerning since AMR, is on the increase in India and still poses a serious threat to public health in terms of death and monetary loss. The Indian government recognized the importance of rapid tests that provide timely and accurate diagnoses and can shorten the time it takes to identify the infection and enable more effective antibiotic therapy. A need for POC diagnostic tests to direct antibiotic prescriptions, in both rural and urban settings.
The China market dominated the Asia Pacific Antimicrobial Resistance Diagnostics Market by Country in 2021; thereby, achieving a market value of $413.4 million by 2028. The Japan market is registering a CAGR of 6.5% during (2022-2028). Additionally, The India market would showcase a CAGR of 7.8% during (2022-2028).
Based on Technology, the market is segmented into PCR, Immunoassay, NGS, Microbiology Culture, Mass Spectrometry, Rapid & Point of Care and Others. Based on End-user, the market is segmented into Hospitals, Diagnostic Laboratories and Pharmaceutical, Biotechnology Companies & Others. Based on Pathogen, the market is segmented into Methicillin Resistant Staphylococcus Aureus (MRSA), Clostridium Difficile (CD), Drug Resistant Campylobacter (DRC), Drug Resistant Streptococcus Pneumoniae (DRSP), Drug Resistant Neisseria Gonorrhoeae (DRNG), Drug Resistant Salmonella (DRNTS) and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Abbott Laboratories, BioMérieux S.A., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Danaher Corporation, Accelerate Diagnostics, Inc., Hologic, Inc., Visby Medical, Inc., Vela Diagnostics Pte. Ltd. (Luye Medical Group Co., Ltd) and Molsid S.A.S.
The use of antibiotics in the management of chronic diseases such as diabetes, rheumatoid arthritis, and asthma as well as organ transplants, joint replacements, and cancer therapy all depend on this ability. Sometimes there is no cure for certain infections. Healthcare professionals would no longer be capable of treating infections and managing these risks to public health if antifungals and antibiotics lost their effectiveness.
Diagnostics enable the right use of novel medications when they are brought into medical care all through their commercial lifecycle. It is crucial for medical professionals and treating doctors to know patient-specific beneficial treatments. Similarly, it is crucial for antimicrobial stewardship boards to know how to fulfil the needs of all patients at the institutions with regard to resistance. Even if a drug were available and capable of saving patients' lives, it might not be taken at all or be misused without a diagnostic tool that can determine if a patient will likely benefit from it.
As it restricts the access of patients and settings to antimicrobials to only those situations in which the medications are likely to enhance an individual's health condition, appropriate usage is fundamental in the control of antimicrobial resistance. The likelihood that a drug's effectiveness will decrease owing to resistance increases the more inadequately antimicrobials are used. Diagnostics aid the medical community in maintaining the usefulness of these priceless medications due to the enormous number of resources and time needed to identify new effective and safe antibiotics.
Several patients in India can no longer receive an advantage from carbapenem, a potent antibiotic used mostly in intensive care units to treat pneumonia and septicemia since they have grown resistant to it. This was stated in research by the Indian Council of Medical Research (ICMR). This is concerning since AMR, is on the increase in India and still poses a serious threat to public health in terms of death and monetary loss. The Indian government recognized the importance of rapid tests that provide timely and accurate diagnoses and can shorten the time it takes to identify the infection and enable more effective antibiotic therapy. A need for POC diagnostic tests to direct antibiotic prescriptions, in both rural and urban settings.
The China market dominated the Asia Pacific Antimicrobial Resistance Diagnostics Market by Country in 2021; thereby, achieving a market value of $413.4 million by 2028. The Japan market is registering a CAGR of 6.5% during (2022-2028). Additionally, The India market would showcase a CAGR of 7.8% during (2022-2028).
Based on Technology, the market is segmented into PCR, Immunoassay, NGS, Microbiology Culture, Mass Spectrometry, Rapid & Point of Care and Others. Based on End-user, the market is segmented into Hospitals, Diagnostic Laboratories and Pharmaceutical, Biotechnology Companies & Others. Based on Pathogen, the market is segmented into Methicillin Resistant Staphylococcus Aureus (MRSA), Clostridium Difficile (CD), Drug Resistant Campylobacter (DRC), Drug Resistant Streptococcus Pneumoniae (DRSP), Drug Resistant Neisseria Gonorrhoeae (DRNG), Drug Resistant Salmonella (DRNTS) and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Abbott Laboratories, BioMérieux S.A., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Danaher Corporation, Accelerate Diagnostics, Inc., Hologic, Inc., Visby Medical, Inc., Vela Diagnostics Pte. Ltd. (Luye Medical Group Co., Ltd) and Molsid S.A.S.
Scope of the Study
By Technology
- PCR
- Immunoassay
- NGS
- Microbiology Culture
- Mass Spectrometry
- Rapid & Point of Care
- Others
By End-user
- Hospitals
- Diagnostic Laboratories
- Pharmaceutical, Biotechnology Companies & Others
By Pathogen
- Methicillin Resistant Staphylococcus Aureus (MRSA)
- Clostridium Difficile (CD)
- Drug Resistant Campylobacter (DRC)
- Drug Resistant Streptococcus Pneumoniae (DRSP)
- Drug Resistant Neisseria Gonorrhoeae (DRNG)
- Drug Resistant Salmonella (DRNTS)
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- BioMérieux S.A.
- F.Hoffmann-La Roche Ltd.
- Becton, Dickinson and Company
- Danaher Corporation
- Accelerate Diagnostics, Inc.
- Hologic, Inc.
- Visby Medical, Inc.
- Vela Diagnostics Pte. Ltd. (Luye Medical Group Co., Ltd)
- Molsid S.A.S.
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. Asia Pacific Antimicrobial Resistance Diagnostics Market by Technology
Chapter 5. Asia Pacific Antimicrobial Resistance Diagnostics Market by End-user
Chapter 6. Asia Pacific Antimicrobial Resistance Diagnostics Market by Pathogen
Chapter 7. Asia Pacific Antimicrobial Resistance Diagnostics Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Abbott Laboratories
- BioMérieux S.A.
- F. Hoffmann-La Roche Ltd.
- Becton, Dickinson and Company
- Danaher Corporation
- Accelerate Diagnostics, Inc.
- Hologic, Inc.
- Visby Medical, Inc.
- Vela Diagnostics Pte. Ltd. (Luye Medical Group Co., Ltd)
- Molsid S.A.S.
Methodology
LOADING...
